|Bid||38.50 x 3200|
|Ask||38.60 x 800|
|Day's range||38.14 - 43.54|
|52-week range||25.31 - 141.01|
|Beta (5Y monthly)||-1.44|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.
Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.
Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. Indeed, headlines regarding the new omicron variant of the coronavirus began to surface before Thursday's Thanksgiving holiday. It just took a while for investors to connect the dots all the way back to Vir Biotechnology, which potentially benefits from a renewed outbreak of infections stemming from this new strain of the pandemic-causing virus.